Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin
In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non‐Black patients but also a higher frequency of HCV genotype 1 (GT‐1) infection. The aim of this community‐based study was to determ...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2006-04, Vol.13 (4), p.242-249 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 249 |
|---|---|
| container_issue | 4 |
| container_start_page | 242 |
| container_title | Journal of viral hepatitis |
| container_volume | 13 |
| creator | Bräu, N. Bini, E. J. Currie, S. Shen, H. Schmidt, W. N. King, P. D. Ho, S. B. Cheung, R. C. Hu, K.-Q. Anand, B. S. Simon, F. R. Aytaman, A. Johnson, D. P. Awad, J. A. Ahmad, J. Mendenhall, C. L. Pedrosa, M. C. Moseley, R. H. Hagedorn, C. H. Waters, B. Chang, K.-M. Morgan, T. R. Rossi, S. J. Jeffers, L. J. Wright, T. L. |
| description | In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non‐Black patients but also a higher frequency of HCV genotype 1 (GT‐1) infection. The aim of this community‐based study was to determine whether Black patients have a lower SVR rate independent of genotype. We prospectively enrolled 785 patients (24.8% Black, 71.5% White, 3.7% others) who received interferon alpha‐2b 3 MU three times weekly + RBV 1000–1200 mg/day for 24 weeks (GT‐2/3) or 48 weeks (GT‐1). Black patients were more commonly infected with GT‐1 (86.8%vs 64.8%, P |
| doi_str_mv | 10.1111/j.1365-2893.2005.00682.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17181169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17181169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4352-f6c70658c5bcbac6231563c6f5ce2d479030454875cfa1756b087595749bad6e3</originalsourceid><addsrcrecordid>eNqNUcFu1DAUjBCIlsIvoHfi1GztJHYSiQtEsAVVcCmlN8txXlhvs3ZqO-3uN_MTOLurIm5YlvzkNzNv7EkSoGRB47pYL2jOWZpVdb7ICGELQniVLbbPktOnxvO5ZllKGClOklferwmhecboy-SEch5lanKa_P44SHUHowwaTfDwqMMK1MpZoxWscL4P2kMDK_mAIGGwj-jATz5IbbCDB-3kAA79aI1HcDIghJU0YKxJ99pHzV9obNiNCPQc2ilEEIKXG_y36yG7yM9Bmi4C4ty4YwNwOw6Hee0ONtYh9A7vp-gYOjuPxW5SQUcLYHvQJqDrMb5hL-R0K6NNbV4nL3o5eHxzPM-SH58_XTeX6dX35Zfmw1WqivnDeq5KwlmlWKtaqXiWU8ZzxXumMOuKsiY5KVhRlUz1kpaMtyTWNSuLupUdx_wseXfQHZ2NJn0QG-0VDoM0aCcvaEkrSnkdgdUBqJz13mEvRqc30u0EJWIOWqzFnKeY8xRz0GIftNhG6tvjjKndYPeXeEw2At4fAI96wN1_C4uvN5exiPT0QNc-4PaJLt2d4GVeMvHz21I0y9vb-ua6EU3-B_UIym4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17181169</pqid></control><display><type>article</type><title>Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bräu, N. ; Bini, E. J. ; Currie, S. ; Shen, H. ; Schmidt, W. N. ; King, P. D. ; Ho, S. B. ; Cheung, R. C. ; Hu, K.-Q. ; Anand, B. S. ; Simon, F. R. ; Aytaman, A. ; Johnson, D. P. ; Awad, J. A. ; Ahmad, J. ; Mendenhall, C. L. ; Pedrosa, M. C. ; Moseley, R. H. ; Hagedorn, C. H. ; Waters, B. ; Chang, K.-M. ; Morgan, T. R. ; Rossi, S. J. ; Jeffers, L. J. ; Wright, T. L.</creator><creatorcontrib>Bräu, N. ; Bini, E. J. ; Currie, S. ; Shen, H. ; Schmidt, W. N. ; King, P. D. ; Ho, S. B. ; Cheung, R. C. ; Hu, K.-Q. ; Anand, B. S. ; Simon, F. R. ; Aytaman, A. ; Johnson, D. P. ; Awad, J. A. ; Ahmad, J. ; Mendenhall, C. L. ; Pedrosa, M. C. ; Moseley, R. H. ; Hagedorn, C. H. ; Waters, B. ; Chang, K.-M. ; Morgan, T. R. ; Rossi, S. J. ; Jeffers, L. J. ; Wright, T. L. ; VA-HCV-001 Study Group ; The VA‐HCV‐001 Study Group</creatorcontrib><description><![CDATA[In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non‐Black patients but also a higher frequency of HCV genotype 1 (GT‐1) infection. The aim of this community‐based study was to determine whether Black patients have a lower SVR rate independent of genotype. We prospectively enrolled 785 patients (24.8% Black, 71.5% White, 3.7% others) who received interferon alpha‐2b 3 MU three times weekly + RBV 1000–1200 mg/day for 24 weeks (GT‐2/3) or 48 weeks (GT‐1). Black patients were more commonly infected with GT‐1 (86.8%vs 64.8%, P < 0.001) and less frequently had an SVR compared with non‐Black patients (8.4%vs 21.6%, P < 0.001). Within GT‐1, Black patients had a lower SVR rate than non‐Black patients (6.1%vs 14.1%, P = 0.004) but not within GT‐2/3 (50.0%vs 36.5%, P = 0.47). Black patients had lower baseline haemoglobin levels (14.8 vs 15.3 g/dL, P < 0.001) and neutrophil counts (2900 vs 4100/mm3, P < 0.001) and required more frequent dose reductions of RBV (29.8%vs 18.5%, P < 0.001) and interferon (4.7%vs 1.6%, P = 0.012). However, dose reductions were not associated with lower SVR rates while early treatment discontinuations were (2.9%vs 25.7%, P < 0.001). Independent predictors of SVR were GT‐1 [odds ratio (OR) 0.33; 95% confidence interval (CI) 0.20–0.55; P < 0.001], Black race (OR 0.45; 95% CI 0.22–0.93; P = 0.030), and advanced fibrosis, stages 3 + 4 (OR 0.53; 95% CI 0.31–0.92; P = 0.023). In conclusion, Black patients infected with HCV GT‐1 (but not GT‐2/3) have a lower SVR rate than non‐Black patients. This is not explained by their lower baseline haemoglobin levels and neutrophil counts that lead to higher rates of ribavirin and interferon dose reductions.]]></description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/j.1365-2893.2005.00682.x</identifier><identifier>PMID: 16611190</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>African Continental Ancestry Group ; Alanine Transaminase - blood ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Biopsy ; community-based practice ; dose reduction ; Dose-Response Relationship, Drug ; European Continental Ancestry Group ; Female ; Genotype ; Hepacivirus - genetics ; hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; Liver Cirrhosis - pathology ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Prospective Studies ; racial differences ; Ribavirin - administration & dosage ; Ribavirin - adverse effects ; RNA, Viral - blood ; therapy</subject><ispartof>Journal of viral hepatitis, 2006-04, Vol.13 (4), p.242-249</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4352-f6c70658c5bcbac6231563c6f5ce2d479030454875cfa1756b087595749bad6e3</citedby><cites>FETCH-LOGICAL-c4352-f6c70658c5bcbac6231563c6f5ce2d479030454875cfa1756b087595749bad6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2893.2005.00682.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2893.2005.00682.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16611190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bräu, N.</creatorcontrib><creatorcontrib>Bini, E. J.</creatorcontrib><creatorcontrib>Currie, S.</creatorcontrib><creatorcontrib>Shen, H.</creatorcontrib><creatorcontrib>Schmidt, W. N.</creatorcontrib><creatorcontrib>King, P. D.</creatorcontrib><creatorcontrib>Ho, S. B.</creatorcontrib><creatorcontrib>Cheung, R. C.</creatorcontrib><creatorcontrib>Hu, K.-Q.</creatorcontrib><creatorcontrib>Anand, B. S.</creatorcontrib><creatorcontrib>Simon, F. R.</creatorcontrib><creatorcontrib>Aytaman, A.</creatorcontrib><creatorcontrib>Johnson, D. P.</creatorcontrib><creatorcontrib>Awad, J. A.</creatorcontrib><creatorcontrib>Ahmad, J.</creatorcontrib><creatorcontrib>Mendenhall, C. L.</creatorcontrib><creatorcontrib>Pedrosa, M. C.</creatorcontrib><creatorcontrib>Moseley, R. H.</creatorcontrib><creatorcontrib>Hagedorn, C. H.</creatorcontrib><creatorcontrib>Waters, B.</creatorcontrib><creatorcontrib>Chang, K.-M.</creatorcontrib><creatorcontrib>Morgan, T. R.</creatorcontrib><creatorcontrib>Rossi, S. J.</creatorcontrib><creatorcontrib>Jeffers, L. J.</creatorcontrib><creatorcontrib>Wright, T. L.</creatorcontrib><creatorcontrib>VA-HCV-001 Study Group</creatorcontrib><creatorcontrib>The VA‐HCV‐001 Study Group</creatorcontrib><title>Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description><![CDATA[In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non‐Black patients but also a higher frequency of HCV genotype 1 (GT‐1) infection. The aim of this community‐based study was to determine whether Black patients have a lower SVR rate independent of genotype. We prospectively enrolled 785 patients (24.8% Black, 71.5% White, 3.7% others) who received interferon alpha‐2b 3 MU three times weekly + RBV 1000–1200 mg/day for 24 weeks (GT‐2/3) or 48 weeks (GT‐1). Black patients were more commonly infected with GT‐1 (86.8%vs 64.8%, P < 0.001) and less frequently had an SVR compared with non‐Black patients (8.4%vs 21.6%, P < 0.001). Within GT‐1, Black patients had a lower SVR rate than non‐Black patients (6.1%vs 14.1%, P = 0.004) but not within GT‐2/3 (50.0%vs 36.5%, P = 0.47). Black patients had lower baseline haemoglobin levels (14.8 vs 15.3 g/dL, P < 0.001) and neutrophil counts (2900 vs 4100/mm3, P < 0.001) and required more frequent dose reductions of RBV (29.8%vs 18.5%, P < 0.001) and interferon (4.7%vs 1.6%, P = 0.012). However, dose reductions were not associated with lower SVR rates while early treatment discontinuations were (2.9%vs 25.7%, P < 0.001). Independent predictors of SVR were GT‐1 [odds ratio (OR) 0.33; 95% confidence interval (CI) 0.20–0.55; P < 0.001], Black race (OR 0.45; 95% CI 0.22–0.93; P = 0.030), and advanced fibrosis, stages 3 + 4 (OR 0.53; 95% CI 0.31–0.92; P = 0.023). In conclusion, Black patients infected with HCV GT‐1 (but not GT‐2/3) have a lower SVR rate than non‐Black patients. This is not explained by their lower baseline haemoglobin levels and neutrophil counts that lead to higher rates of ribavirin and interferon dose reductions.]]></description><subject>African Continental Ancestry Group</subject><subject>Alanine Transaminase - blood</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Biopsy</subject><subject>community-based practice</subject><subject>dose reduction</subject><subject>Dose-Response Relationship, Drug</subject><subject>European Continental Ancestry Group</subject><subject>Female</subject><subject>Genotype</subject><subject>Hepacivirus - genetics</subject><subject>hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>Liver Cirrhosis - pathology</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Prospective Studies</subject><subject>racial differences</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - adverse effects</subject><subject>RNA, Viral - blood</subject><subject>therapy</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcFu1DAUjBCIlsIvoHfi1GztJHYSiQtEsAVVcCmlN8txXlhvs3ZqO-3uN_MTOLurIm5YlvzkNzNv7EkSoGRB47pYL2jOWZpVdb7ICGELQniVLbbPktOnxvO5ZllKGClOklferwmhecboy-SEch5lanKa_P44SHUHowwaTfDwqMMK1MpZoxWscL4P2kMDK_mAIGGwj-jATz5IbbCDB-3kAA79aI1HcDIghJU0YKxJ99pHzV9obNiNCPQc2ilEEIKXG_y36yG7yM9Bmi4C4ty4YwNwOw6Hee0ONtYh9A7vp-gYOjuPxW5SQUcLYHvQJqDrMb5hL-R0K6NNbV4nL3o5eHxzPM-SH58_XTeX6dX35Zfmw1WqivnDeq5KwlmlWKtaqXiWU8ZzxXumMOuKsiY5KVhRlUz1kpaMtyTWNSuLupUdx_wseXfQHZ2NJn0QG-0VDoM0aCcvaEkrSnkdgdUBqJz13mEvRqc30u0EJWIOWqzFnKeY8xRz0GIftNhG6tvjjKndYPeXeEw2At4fAI96wN1_C4uvN5exiPT0QNc-4PaJLt2d4GVeMvHz21I0y9vb-ua6EU3-B_UIym4</recordid><startdate>200604</startdate><enddate>200604</enddate><creator>Bräu, N.</creator><creator>Bini, E. J.</creator><creator>Currie, S.</creator><creator>Shen, H.</creator><creator>Schmidt, W. N.</creator><creator>King, P. D.</creator><creator>Ho, S. B.</creator><creator>Cheung, R. C.</creator><creator>Hu, K.-Q.</creator><creator>Anand, B. S.</creator><creator>Simon, F. R.</creator><creator>Aytaman, A.</creator><creator>Johnson, D. P.</creator><creator>Awad, J. A.</creator><creator>Ahmad, J.</creator><creator>Mendenhall, C. L.</creator><creator>Pedrosa, M. C.</creator><creator>Moseley, R. H.</creator><creator>Hagedorn, C. H.</creator><creator>Waters, B.</creator><creator>Chang, K.-M.</creator><creator>Morgan, T. R.</creator><creator>Rossi, S. J.</creator><creator>Jeffers, L. J.</creator><creator>Wright, T. L.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>200604</creationdate><title>Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin</title><author>Bräu, N. ; Bini, E. J. ; Currie, S. ; Shen, H. ; Schmidt, W. N. ; King, P. D. ; Ho, S. B. ; Cheung, R. C. ; Hu, K.-Q. ; Anand, B. S. ; Simon, F. R. ; Aytaman, A. ; Johnson, D. P. ; Awad, J. A. ; Ahmad, J. ; Mendenhall, C. L. ; Pedrosa, M. C. ; Moseley, R. H. ; Hagedorn, C. H. ; Waters, B. ; Chang, K.-M. ; Morgan, T. R. ; Rossi, S. J. ; Jeffers, L. J. ; Wright, T. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4352-f6c70658c5bcbac6231563c6f5ce2d479030454875cfa1756b087595749bad6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>African Continental Ancestry Group</topic><topic>Alanine Transaminase - blood</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Biopsy</topic><topic>community-based practice</topic><topic>dose reduction</topic><topic>Dose-Response Relationship, Drug</topic><topic>European Continental Ancestry Group</topic><topic>Female</topic><topic>Genotype</topic><topic>Hepacivirus - genetics</topic><topic>hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>Liver Cirrhosis - pathology</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Prospective Studies</topic><topic>racial differences</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - adverse effects</topic><topic>RNA, Viral - blood</topic><topic>therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bräu, N.</creatorcontrib><creatorcontrib>Bini, E. J.</creatorcontrib><creatorcontrib>Currie, S.</creatorcontrib><creatorcontrib>Shen, H.</creatorcontrib><creatorcontrib>Schmidt, W. N.</creatorcontrib><creatorcontrib>King, P. D.</creatorcontrib><creatorcontrib>Ho, S. B.</creatorcontrib><creatorcontrib>Cheung, R. C.</creatorcontrib><creatorcontrib>Hu, K.-Q.</creatorcontrib><creatorcontrib>Anand, B. S.</creatorcontrib><creatorcontrib>Simon, F. R.</creatorcontrib><creatorcontrib>Aytaman, A.</creatorcontrib><creatorcontrib>Johnson, D. P.</creatorcontrib><creatorcontrib>Awad, J. A.</creatorcontrib><creatorcontrib>Ahmad, J.</creatorcontrib><creatorcontrib>Mendenhall, C. L.</creatorcontrib><creatorcontrib>Pedrosa, M. C.</creatorcontrib><creatorcontrib>Moseley, R. H.</creatorcontrib><creatorcontrib>Hagedorn, C. H.</creatorcontrib><creatorcontrib>Waters, B.</creatorcontrib><creatorcontrib>Chang, K.-M.</creatorcontrib><creatorcontrib>Morgan, T. R.</creatorcontrib><creatorcontrib>Rossi, S. J.</creatorcontrib><creatorcontrib>Jeffers, L. J.</creatorcontrib><creatorcontrib>Wright, T. L.</creatorcontrib><creatorcontrib>VA-HCV-001 Study Group</creatorcontrib><creatorcontrib>The VA‐HCV‐001 Study Group</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bräu, N.</au><au>Bini, E. J.</au><au>Currie, S.</au><au>Shen, H.</au><au>Schmidt, W. N.</au><au>King, P. D.</au><au>Ho, S. B.</au><au>Cheung, R. C.</au><au>Hu, K.-Q.</au><au>Anand, B. S.</au><au>Simon, F. R.</au><au>Aytaman, A.</au><au>Johnson, D. P.</au><au>Awad, J. A.</au><au>Ahmad, J.</au><au>Mendenhall, C. L.</au><au>Pedrosa, M. C.</au><au>Moseley, R. H.</au><au>Hagedorn, C. H.</au><au>Waters, B.</au><au>Chang, K.-M.</au><au>Morgan, T. R.</au><au>Rossi, S. J.</au><au>Jeffers, L. J.</au><au>Wright, T. L.</au><aucorp>VA-HCV-001 Study Group</aucorp><aucorp>The VA‐HCV‐001 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2006-04</date><risdate>2006</risdate><volume>13</volume><issue>4</issue><spage>242</spage><epage>249</epage><pages>242-249</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract><![CDATA[In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non‐Black patients but also a higher frequency of HCV genotype 1 (GT‐1) infection. The aim of this community‐based study was to determine whether Black patients have a lower SVR rate independent of genotype. We prospectively enrolled 785 patients (24.8% Black, 71.5% White, 3.7% others) who received interferon alpha‐2b 3 MU three times weekly + RBV 1000–1200 mg/day for 24 weeks (GT‐2/3) or 48 weeks (GT‐1). Black patients were more commonly infected with GT‐1 (86.8%vs 64.8%, P < 0.001) and less frequently had an SVR compared with non‐Black patients (8.4%vs 21.6%, P < 0.001). Within GT‐1, Black patients had a lower SVR rate than non‐Black patients (6.1%vs 14.1%, P = 0.004) but not within GT‐2/3 (50.0%vs 36.5%, P = 0.47). Black patients had lower baseline haemoglobin levels (14.8 vs 15.3 g/dL, P < 0.001) and neutrophil counts (2900 vs 4100/mm3, P < 0.001) and required more frequent dose reductions of RBV (29.8%vs 18.5%, P < 0.001) and interferon (4.7%vs 1.6%, P = 0.012). However, dose reductions were not associated with lower SVR rates while early treatment discontinuations were (2.9%vs 25.7%, P < 0.001). Independent predictors of SVR were GT‐1 [odds ratio (OR) 0.33; 95% confidence interval (CI) 0.20–0.55; P < 0.001], Black race (OR 0.45; 95% CI 0.22–0.93; P = 0.030), and advanced fibrosis, stages 3 + 4 (OR 0.53; 95% CI 0.31–0.92; P = 0.023). In conclusion, Black patients infected with HCV GT‐1 (but not GT‐2/3) have a lower SVR rate than non‐Black patients. This is not explained by their lower baseline haemoglobin levels and neutrophil counts that lead to higher rates of ribavirin and interferon dose reductions.]]></abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16611190</pmid><doi>10.1111/j.1365-2893.2005.00682.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2006-04, Vol.13 (4), p.242-249 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17181169 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | African Continental Ancestry Group Alanine Transaminase - blood Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Biopsy community-based practice dose reduction Dose-Response Relationship, Drug European Continental Ancestry Group Female Genotype Hepacivirus - genetics hepatitis C Hepatitis C virus Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Liver Cirrhosis - pathology Logistic Models Male Middle Aged Multivariate Analysis Prospective Studies racial differences Ribavirin - administration & dosage Ribavirin - adverse effects RNA, Viral - blood therapy |
| title | Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T07%3A44%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Black%20patients%20with%20chronic%20hepatitis%20C%20have%20a%20lower%20sustained%20viral%20response%20rate%20than%20non-Blacks%20with%20genotype%201,%20but%20the%20same%20with%20genotypes%202/3,%20and%20this%20is%20not%20explained%20by%20more%20frequent%20dose%20reductions%20of%20interferon%20and%20ribavirin&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Br%C3%A4u,%20N.&rft.aucorp=VA-HCV-001%20Study%20Group&rft.date=2006-04&rft.volume=13&rft.issue=4&rft.spage=242&rft.epage=249&rft.pages=242-249&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/j.1365-2893.2005.00682.x&rft_dat=%3Cproquest_cross%3E17181169%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17181169&rft_id=info:pmid/16611190&rfr_iscdi=true |